Modes of infection and oncogenesis by the Epstein-Barr virus

Reviews in Medical Virology

Volumn 24, Issue 4, 2014, Pages 242-253

  Murata, Takayuki ^a,b   Sato, Yoshitaka ^a   Kimura, Hiroshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; ONCOGENE; T CELL LYMPHOMA; VIRUS ACTIVATION; VIRUS GENOME; VIRUS LATENCY; GENETIC EPIGENESIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE EVASION; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

CARCINOGENESIS; CELL TRANSFORMATION, VIRAL; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; VIRUS LATENCY;

EID: 84903821266     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1786     Document Type: Article

References (131)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40years on. Nature reviews Cancer 2004; 4: 757-768.
2. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nature reviews Immunology 2003; 3; 801-812.
3. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003; 22: 5108-5121.
4. Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011; 17: 3056-3063.
5. Soni V, Cahir-McFarland E, Kieff E. LMP1 TRAFficking activates growth and survival pathways. Advances in Experimental Medicine and Biology 2007; 597: 173-187.
6. Portis T, Ikeda M, Longnecker R. Epstein-Barr virus LMP2A: regulating cellular ubiquitination processes for maintenance of viral latency? Trends in Immunology 2004; 25: 422-426.
7. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 1919-1924.
8. Skalska L, White RE, Parker GA, Sinclair AJ, Paschos K, Allday MJ. Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathogens 2013; 9: e1003187.
9. Takada K. Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Seminars in Cancer Biology 2012; 22: 162-165.
10. Marquitz AR, Raab-Traub N. The role of miRNAs and EBV BARTs in NPC. Seminars in Cancer Biology 2012; 22: 166-172.
11. Lo AK, Dawson CW, Jin DY, Lo KW. The pathological roles of BART miRNAs in nasopharyngeal carcinoma, The Journal of Pathology 2012; 227: 392-403.
12. Lopes LF, Ruiz Miyazawa KW, de Almeida ER, et al. Epstein-Barr virus (EBV) microRNAs: involvement in cancer pathogenesis and immunopathology. International Reviews of Immunology 2013; 32: 271-281.
13. Vereide DT, Seto E, Chiu YF, et al. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 2013. DOI: 10.1038/onc.2013.71
14. Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Letters 2011; 305: 163-174.
15. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Human Pathology 2002; 33: 392-404.
16. Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. British Journal of Haematology 2011; 152: 13-30.
17. Latour S. Natural killer T cells and X-linked lymphoproliferative syndrome. Current Opinion in Allergy and Clinical Immunology 2007; 7: 510-514.
18. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
19. Croft NP, Shannon-Lowe C, Bell AI, et al. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathogens 2009; 5: e1000490.
20. Ressing ME, Horst D, Griffin BD, et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Seminars in Cancer Biology 2008; 18: 397-408.
21. Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Seminars in Cancer Biology 2008; 18: 388-396.
22. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nature reviews Immunology. 2001; 1: 75-82.
23. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. International Journal of Cancer Journal International du Cancer 2006; 118: 1853-1861.
24. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006; 72: 1605-1621.
25. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Experimental Hematology 2006; 34: 399-406.
26. Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathology, Research and Practice 2011; 207: 529-537.
27. Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas. Seminars in Cancer Biology 2012; 22: 127-136.
28. Callan MF, Steven N, Krausa P, et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nature Medicine 1996; 2: 906-911.
29. Foss HD, Herbst H, Hummel M, et al. Patterns of cytokine gene expression in infectious mononucleosis. Blood 1994; 83: 707-712.
30. Imadome K, Yajima M, Arai A, et al. Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathogens 2011; 7: e1002326.
31. Rowe M, Kelly GL, Bell AI, Rickinson AB. Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Seminars in Cancer Biology 2009; 19: 377-388.
32. Gruhne B, Kamranvar SA, Masucci MG, Sompallae R. EBV and genomic instability--a new look at the role of the virus in the pathogenesis of Burkitt's lymphoma. Seminars in Cancer Biology 2009; 19: 394-400.
33. Uozaki H, Fukayama M. Epstein-Barr virus and gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. International Journal of Clinical and Experimental Pathology 2008; 1: 198-216.
34. Hildesheim A, Apple RJ, Chen CJ, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. Journal of the National Cancer Institute 2002; 94: 1780-1789.
35. Goldsmith DB, West TM, Morton, R. HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis. Clinical Otolaryngology and Allied Sciences 2002; 27: 61-67.
36. Huang X, Kushekhar K, Nolte I, et al. HLA associations in classical Hodgkin lymphoma: EBV status matters. PloS One 2012; 7: e39986.
37. Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+Hodgkin lymphoma. Blood 2007; 110: 3310-3315.
38. Hjalgrim H, Rostgaard K, Johnson PC, et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 6400-6405.
39. Koriyama C, Shinkura R, Hamasaki Y, Fujiyoshi T, Eizuru Y, Tokunaga M. Human leukocyte antigens related to Epstein-Barr virus-associated gastric carcinoma in Japanese patients. European Journal of Cancer Prevention 2001; 10: 69-75.
40. Gruhne B, Sompallae R, Masucci MG. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 2009; 28: 3997-4008.
41. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Seminars in Cancer Biology 2009; 19: 158-164.
42. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. Leukemia & Lymphoma 2013; 54: 2035-2040.
43. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Reviews in Medical Virology 2005; 15: 3-15.
44. Heuts F, Rottenberg ME, Salamon D, et al. T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. Journal of Virology 2014. DOI: 10.1128/JVI.02885-13
45. Takacs M, Banati F, Koroknai A, et al. Epigenetic regulation of latent Epstein-Barr virus promoters. Biochimica et Biophysica Acta 2010; 1799: 228-235.
46. Katsumura KR, Maruo S, Takada K. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes. Journal of Medical Virology 2012; 84: 504-510.
47. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 850-855.
48. Ma SD, Hegde S, Young KH, et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. Journal of Virology 2011; 85: 165-177.
49. Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T, Takada K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. Journal of Virology 2007; 81: 1037-1042.
50. Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB, Rowe M. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. Journal of Virology 2009; 83: 7749-7760.
51. Tsang CM, Zhang G, Seto E, et al. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. International Journal of Cancer Journal International du Cancer 2010; 127: 1570-1583.
52. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nature Genetics 2004; 36: 1099-1104.
53. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC. Methylation-dependent binding of the Epstein-Barr virus BZLF1 protein to viral promoters. PLoS Pathogens 2009; 5: e1000356.
54. Bergbauer M, Kalla M, Schmeinck A, et al. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathogens 2010; 6: e1001114.
55. Woellmer A, Arteaga-Salas JM, Hammerschmidt W. BZLF1 governs CpG-methylated chromatin of Epstein-Barr virus reversing epigenetic repression PLoS Pathogens 2012; 8: e1002902.
56. Fernandez AF, Rosales C, Lopez-Nieva P, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Research 2009; 19: 438-451.
57. Murata T, Tsurumi T. Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latency. Frontiers in Genetics 2013; 4: 53.
58. Murata T, Kondo Y, Sugimoto A, et al. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. Journal of Virology 2012; 86: 4752-4761.
59. Sinclair AJ. Epigenetic control of Epstein-Barr virus transcription-relevance to viral life cycle? Frontiers in Genetics 2013; 4: 161.
60. Arvey A, Tempera I, Tsai K, et al. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host & Microbe 2012; 12: 233-245.
61. Ramasubramanyan S, Osborn K, Flower K, Sinclair AJ. Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. Journal of Virology 2012; 86: 1809-1819.
62. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000; 13: 497-506.
63. Yoshiyama H, Shimizu N, Takada K. Persistent Epstein-Barr virus infection in a human T-cell line: unique program of latent virus expression. The EMBO Journal 1995; 14: 3706-3711.
64. Noda C, Murata T, Kanda T, et al. Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1. The Journal of Biological Chemistry 2011; 286: 42524-42533.
65. Yoshiyama H, Imai S, Shimizu N, Takada K. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. Journal of Virology 1997; 71: 5688-5691.
66. Tierney R, Kirby H, Nagra J, Rickinson A, Bell A. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. Journal of Virology 2000; 74: 10458-10467.
67. Tierney R, Nagra J, Hutchings I, et al. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. Journal of Virology 2007; 81: 10092-10100.
68. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. Journal of Virology 1995; 69: 253-262.
69. Eliopoulos AG, Stack M, Dawson CW, et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997; 14: 2899-2916.
70. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. The Journal of Biological Chemistry 1999; 274: 16085-16096.
71. Liu MT, Chen YR, Chen SC, et al. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004; 23: 2531-2539.
72. Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states. Reviews in Medical Virology 2013. DOI: 10.1002/rmv.1780
73. Sato Y, Tsurumi T. Genome guardian p53 and viral infections. Reviews in Medical Virology 2013; 23: 213-220.
74. Chang YH, Lee CP, Su MT, et al. Epstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality. PloS One 2012; 7: e39217.
75. Wu CC, Liu MT, Chang YT, et al. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Research 2010; 38: 1932-1949.
76. Ma SD, Yu X, Mertz JE, et al. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. Journal of Virology 2012; 86: 7976-7987.
77. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. The EMBO Journal 1987; 6: 2743-2751.
78. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nature Reviews Immunology 2008; 8: 22-33.
79. Kis LL, Takahara M, Nagy N, Klein G, Klein E. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunology Letters 2006; 104: 83-88.
80. Kis LL, Takahara M, Nagy N, Klein G, Klein E. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 2006; 107: 2928-2935.
81. Kis LL, Salamon D, Persson EK, et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 872-877.
82. Johansson P, Jansson A, Ruetschi U, Rymo L. The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene. Journal of Virology 2010; 84: 2787-2797.
83. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702-703.
84. Chapman CJ, Mockridge CI, Rowe M, Rickinson AB, Stevenson FK. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood 1995; 85: 2176-2181.
85. Harris RS, Croom-Carter DS, Rickinson AB, Neuberger MS. Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells. Journal of Virology 2001; 75: 10488-10492.
86. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. The Lancet Oncology 2003; 4: 22-29.
87. Egeler RM, de Kraker J, Slater R, Purtilo DT. Documentation of Burkitt lymphoma with t(8;14) (q24;q32) in X-linked lymphoproliferative disease. Cancer 1992; 70: 683-687.
88. Gaidano G, Ballerini P, Gong JZ, et al. p53 Mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 5413-5417.
89. Cinti C, Leoncini L, Nyongo A, et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. The American Journal of Pathology 2000; 156: 751-760.
90. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. The Journal of Experimental Medicine 1996; 184: 1495-1505.
91. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999; 286: 300-303.
92. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999; 18: 3063-3070.
93. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-953.
94. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. The Journal of Experimental Medicine 2000; 191: 395-402.
95. Muschen M, Re D, Brauninger A, et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Research 2000; 60: 5640-5643.
96. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. The Journal of Experimental Medicine 2009; 206: 981-989.
97. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002; 99: 1474-1477.
98. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematological Oncology 2005; 23: 61-67.
99. George LC, Rowe M, Fox CP. Epstein-Barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. Current Hematologic Malignancy Reports 2012; 7: 276-284.
100. Fox CP, Shannon-Lowe C, Rowe M. Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2011; 2: 8.
101. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Reviews in Medical Virology 2006; 16: 251-261.
102. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. The Journal of Infectious Diseases 2005; 191: 531-539.
103. Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood 1996; 87: 1446-1457.
104. Tsuge I, Morishima T, Kimura H, Kuzushima K, Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. Journal of Medical Virology 2001; 64: 141-148.
105. Sugaya N, Kimura H, Hara S, et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. The Journal of Infectious Diseases 2004; 190: 985-988.
106. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012; 119: 673-686.
107. Suzuki R. NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Current Oncology Reports 2012; 14: 395-402.
108. Xu ZG, Iwatsuki K, Oyama N, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. British Journal of Cancer 2001; 84: 920-925.
109. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. International Journal of Cancer Journal International du Cancer 1996; 68: 285-290.
110. Ndour PA, Brocqueville G, Ouk TS, et al. Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells. Journal of Virology 2012; 86: 3934-3943.
111. Takahara M, Kis LL, Nagy N, Liu A, Harabuchi Y, Klein G, Klein E. Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. International Journal of Cancer Journal International du Cancer 2006; 119: 2775-2783.
112. Takahara M, Kishibe K, Bandoh N, Nonaka S, Harabuchi Y. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Human Pathology 2004; 35: 86-95.
113. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118: 3195-3204.
114. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discovery 2012; 2: 591-597.
115. Kimura H, Karube K, Ito Y, et al. Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan. Leukemia & Lymphoma 2013. DOI: 10.3109/10428194.2013.819577
116. Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Seminars in Cancer Biology 2012; 22: 79-86.
117. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Seminars in Cancer Biology 2002; 12: 431-441.
118. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Seminars in Cancer Biology 2002; 12: 473-487.
119. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Seminars in Cancer Biology 2002; 12: 451-462.
120. Choi PH, Suen MW, Huang DP, Lo KW, Lee JC. Nasopharyngeal carcinoma: genetic changes, Epstein-Barr virus infection, or both. A clinical and molecular study of 36 patients. Cancer 1993; 72: 2873-2878.
121. Vera-Sempere FJ, Burgos JS, Botella MS, Morera C. Immunohistochemical expression of Bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histology and Histopathology 1997; 12, 9-18.
122. Tsang CM, Yip YL, Lo KW, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: E3473-E3482.
123. Yu MC, Ho JH, Lai SH, Henderson BE. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Research 1986; 46: 956-961.
124. Su WH, Hildesheim A, Chang YS. Human leukocyte antigens and Epstein-Barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. Frontiers in Oncology 2013; 3: 299.
125. Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathology International 2010; 60: 337-350.
126. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr virus (EBV)-associated gastric carcinoma. Viruses 2012; 4: 3420-3439.
127. Oh ST, Seo JS, Moon UY, et al. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 2004; 320: 330-336.
128. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature Genetics 2011; 43: 1219-1223.
129. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Research 2012; 72: 3445-3450.
130. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Research 2002; 62: 6645-6650.
131. Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Research 2009; 69: 2766-2774.